What is the recommended evaluation and treatment for elevated serum prolactin? by Jackson, Jo & Safranek, Sarah
VOL 54, NO 10 / OCTOBER 2005 897w w w. j f p o n l i n e . c o m
CLINICAL INQUIRIES
E V I D E N C E - B A S E D A N S W E R
What is the recommended evaluation and
treatment for elevated serum prolactin?
■ Evidence summary
An expert guideline recommends a history
and physical examination to determine
whether an elevated SPL is due to physio-
logic, pharmacologic, or pathologic causes
(TABLE).1 The fasting morning SPL is least
variable and correlates best with a disease
state.1 Clinical correlation is necessary to
reveal false positives (due to biologically
inactive forms of prolactin) or false nega-
tives (due to very high SPLs that exceed the
ability of the assay). If an elevated SPL is
suspected despite a normal laboratory
report, retesting with serum diluted 1:100
can identify a false-negative value.2
A detailed drug history is important
since drug-induced elevated SPL is com-
mon.1 Laboratory evaluation includes thy-
roid-stimulating hormone, blood urea
nitrogen, and creatinine, as well as preg-
nancy testing when applicable. If no cause
of elevated SPL is identified by initial clin-
ical evaluation or if the SPL is greater than
200 ng/mL, experts recommend imaging
of the sella turcica with computed tomog-
raphy or magnetic resonance imaging.1
Physiologic causes. For patients with a
mildly elevated SPL due to a physiologic
History and physical examination can distinguish
among most physiologic, pharmacologic, or 
pathologic causes of an elevated serum prolactin
level (SPL) (strength of recommendation [SOR]:
C, expert opinion). Patients with unexplained 
elevations of serum prolactin or with a level
above 200 ng/mL should undergo imaging of 
the sella turcica (SOR: C, expert opinion). Mildly
elevated SPL due to physiologic causes may be
managed expectantly (SOR: B, cohort studies)
and pharmacologic elevations may be treated by
discontinuing the causative medication (SOR: C,
expert opinion). Elevated SPL due to pathologic
causes requires both monitoring for complications
and treatment of the underlying condition (SOR:
C, expert opinion). 
Dopamine agonists are effective for patients
requiring drug treatment (SOR: B, systematic
review of cohort studies), and cabergoline 
is more effective and better tolerated than
bromocriptine (SOR: B, randomized controlled
trial [RCT]). Surgery is reserved for symptomatic
patients not controlled medically (SOR: C, 
expert opinion).
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C L I N I C A L C O M M E N T A R Y
Patients with mildly elevated SPLs can be safely
watched with testing and symptom monitoring 
Most elevated prolactin levels in my practice have
been mild and often secondary to medication,
though there are a host of causes, as listed in the
TABLE. This Clinical Inquiry reassures us that
patients with mildly elevated SPLs can be safely
watched with serial testing and monitoring 
symptoms. Obtaining SPLs only on fasting 
specimens can help improve test accuracy. The
feared risk of vision loss due to a macroadenoma
seems to be quite small. Patients with significantly
elevated SPLs with amenorrhea or infertility 
deserve referral to clinicians comfortable with
using dopamine agonists because of the high rate
of success with this treatment. 
Allen Daugird, MD
University of North Carolina at Chapel Hill
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cause, experts recommend expectant man-
agement. Patients should be monitored for
symptoms of hypogonadism (amenorrhea,
infertility, or sexual dysfunction) and have
SPL measured at 6- to 12-month intervals.1
In cohort studies, treatment of the under-
lying cause of elevated SPL reverses second-
ary physiologic changes of low estrogen or
testosterone, and hypogonadism.3–5
Pharmacologic causes. Eliminating a
pharmacologic cause may lead to normal-
ization of SPL, although experts recom-
mend psychiatric consultation before dis-
continuing neuroleptic medications.1
Pathologic causes. Experts advise treat-
ing the underlying cause of a pathologic ele-
vation of SPL. Patients with microadenoma
should have SPLs monitored to prevent
complications of decreased bone mineral
density and sexual dysfunction due to per-
sistently elevated SPL. Patients with a
macroadenoma (>1 cm) are at risk for
tumor growth and require serial imaging
studies in addition to treatment of SPL,
according to expert opinion.1–3
Medical therapy. Medical therapy with
a dopamine agonist is indicated for patients
with either symptoms of hypogonadism due
to elevated SPL, or neurologic symptoms
due to the size of a macroadenoma.1 In a
review of 13 cohort studies, bromo-criptine
improved symptoms and reduced SPLs to
normal for 229 of 280 women (82%).6 A
cohort study of 27 patients with macroade-
nomas treated with bromocriptine found
10% to 50% reductions of tumor size.7 A
randomized controlled trial treating 459
women having hyperprolactinemic amenor-
rhea with either cabergoline or bromocrip-
tine achieved a stable normal SPL in 83%
and 59%, respectively (P<.001). Adverse
effects were common but were less common
with cabergoline (68% vs 78%) and result-
ed in fewer discontinuations (3% vs 12%).8
Surgical therapy. Surgery is indicated
for patients unresponsive to or intolerant
of medical therapy, or who have visual
field loss, cranial nerve palsy, or headache
due to macroadenoma.1 A retrospective
review of patients who underwent surgical
resection found a 40% recurrence rate.9
Recommendations from others
Williams Textbook of Endocrinology
includes the recommendations above and
advises seeking consultation for patients
with mass effects of macroadenomas such as
visual field loss, cranial nerve palsy, or
headaches; for patients with progressive ele-
vation of SPL despite medical treatment; and
for pregnant women.4 Conventional antipsy-
chotic agents are commonly associated with
elevated prolactin due to dopamine agonist
activity. Some atypical antipsychotics may
lead to lower levels of elevated prolactin,
transient elevations or marked elevations.10
Experts recommend following serial SPLs, if
antipsychotics are truly needed. Psychiatric
consultation may assist in making decisions
about medication selection. Patients with
T A B L E
PHYSIOLOGIC
Pregnancy
Ectopic pregnancy
Lactation
Nipple stimulation
Stress
Sleep disorder
PHARMACOLGIC
Dopamine receptor antagonists: phenothiazines, butyrophenones,
thioxanthene, risperidone, metoclopramide, sulpiride, pimozide
Dopamine-depleting agents: α-methyldopa, reserpine
Hormones: estrogens, antiandrogens
Others: danazol, isoniazid, verapamil, cyproheptadine, opiates, 
H2-blockers (cimetidine), cocaine and marijuana, 
tricyclic antidepressants
PATHOLOGIC
Acromegaly
Alcoholic cirrhosis
Chest wall trauma or tumor
Herpes zoster
Hypothalamic and pituitary stalk disease
Hypothyroidism
Pituitary tumors: prolactinomas, adenomas
Polycystic ovarian syndrome
Renal failure
Sarcoidosis
Physiologic, pharmacologic, and pathologic 
causes of an elevated serum prolactin level1
C O N T I N U E D
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symptoms (galactorrhea, amenorrhea,
headaches, visual disturbances, sexual dys-
function) or levels of 200 or more, should
undergo an MRI or CT. Experts recommend
monitoring levels every 1 to 3 months.1
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